TrialThe Lancet. Oncology2023

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.

Eve Rodler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.